Grandfield & Dodd LLC Sells 11,072 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Grandfield & Dodd LLC trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 18.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,945 shares of the medical equipment provider's stock after selling 11,072 shares during the period. Grandfield & Dodd LLC's holdings in Zimmer Biomet were worth $5,064,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZBH. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter valued at $25,000. Dunhill Financial LLC increased its stake in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at $35,000. Finally, Kentucky Trust Co bought a new position in shares of Zimmer Biomet in the 4th quarter worth $39,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research reports. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Stifel Nicolaus upped their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, Raymond James lowered their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus target price of $124.15.

Zimmer Biomet Trading Up 0.7 %

Zimmer Biomet stock traded up $0.72 during trading hours on Wednesday, reaching $104.71. 2,498,389 shares of the company's stock were exchanged, compared to its average volume of 1,893,087. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The firm's 50 day simple moving average is $105.57 and its 200 day simple moving average is $107.26. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The firm has a market capitalization of $20.84 billion, a PE ratio of 23.53, a PEG ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm posted $2.20 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.92%. Zimmer Biomet's payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.